This company listing is no longer active
SYNLAB Valuation
Is SYAB undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of SYAB when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: SYAB (€11.04) is trading above our estimate of fair value (€6.21)
Significantly Below Fair Value: SYAB is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for SYAB?
Key metric: As SYAB is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is SYAB's PE Ratio? | |
|---|---|
| PE Ratio | 27.2x |
| Earnings | €89.35m |
| Market Cap | €2.43b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 1.4x |
| Enterprise Value/EBITDA | 12.6x |
| PEG Ratio | -2.4x |
Price to Earnings Ratio vs Peers
How does SYAB's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 20.6x | ||
FME Fresenius Medical Care | 18.8x | 19.3% | €12.4b |
FRE Fresenius SE KGaA | n/a | 39.0% | €18.8b |
RHK RHÖN-KLINIKUM | 18.6x | 7.5% | €836.7m |
AFX Carl Zeiss Meditec | 24.4x | 16.3% | €5.0b |
SYAB SYNLAB | 27.2x | -11.4% | €2.4b |
Price-To-Earnings vs Peers: SYAB is expensive based on its Price-To-Earnings Ratio (27.2x) compared to the peer average (23x).
Price to Earnings Ratio vs Industry
How does SYAB's PE Ratio compare vs other companies in the European Healthcare Industry?
| 2 Companies | Price / Earnings | Estimated Growth | Market Cap |
|---|---|---|---|
| 2 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Earnings vs Industry: SYAB is expensive based on its Price-To-Earnings Ratio (27.2x) compared to the European Healthcare industry average (18.8x).
Price to Earnings Ratio vs Fair Ratio
What is SYAB's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 27.2x |
| Fair PE Ratio | 15x |
Price-To-Earnings vs Fair Ratio: SYAB is expensive based on its Price-To-Earnings Ratio (27.2x) compared to the estimated Fair Price-To-Earnings Ratio (15x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Shandong Weigao Group Medical Polymer
HK$20.1b
Engages in the research and development, production, wholesale, and sale of medical devices in the People’s Republic of China.
UK2
HK$0.52
7D
-1.0%
1Y
-38.8%
LNA Santé
€244.4m
Engages in the management and operation of health establishments.
2N3
€23.25
7D
-6.1%
1Y
16.0%
Top Glove Corporation Bhd
RM 7.8b
An investment holding company, manufactures, trades in, and sells gloves in Malaysia, Thailand, the People’s Republic of China, and internationally.
5OU
RM 0.98
7D
0.5%
1Y
-82.5%